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Optimised oligonucleotide substrates to assay
XPF-ERCC1 nuclease activity for the discovery
of DNA repair inhibitors†
Adam M. Thomas, ‡abc Sanja Brolih,‡b Joanna F. McGouran, ‡§a
Afaf H. El-Sagheer, ad Denis Ptchelkine,b Morgan Jones,c Neil Q. McDonald,*ce
Peter J. McHugh *b and Tom Brown *a
We report the design and optimisation of novel oligonucleotide
substrates for a sensitive fluorescence assay for high-throughput
screening and functional studies of the DNA repair enzyme, XPF-
ERCC1, with a view to accelerating inhibitor and drug discovery.
Many chemotherapy drugs kill tumour cells through the induction
of DNA damage; DNA interstrand crosslinks (ICLs) are particularly
toxic to cells as they prevent DNA replication and transcription.1
DNA cross-linking drugs, including platinum-based drugs, are
used to treat a range of tumours including many hard-to-treat
cancers (such as pancreatic, oesophageal and lung) for which
survival rates remain low.1,2 DNA repair pathways directly combat
ICL-inducing therapies by removing the toxic DNA damage they
induce,2–5 where resistance to therapy remains a major clinical
problem, limiting the effective use of chemotherapeutic drugs.6
Targeting DNA repair is one of the most compelling, and
poorly exploited strategies for sensitising tumours to ICL-inducing
agents and other chemotherapies.7–9 In particular, increases in
levels of ERCC1 have been linked to poor response to chemo-
therapy across several cancer types in multiple clinical studies.10–13
XPF exists as an obligate heterodimer with ERCC1, forming a
structure selective endonuclease, where XPF is the catalytic
subunit, which preferentially cleaves DNA duplexes adjacent to
a 30 single-stranded flap.14–17 XPF-ERCC1 is involved in a number
of DNA repair pathways including nucleotide excision repair
(NER), homologous recombination (HR) and ICL repair, playing
a critical role in the repair-response to a number of DNA
damaging agents used in cancer therapy.18
Despite the urgent need to explore inhibition of XPF-ERCC1
as a therapeutic avenue, few compounds have been identified
for this purpose.19,20 This is in part due to limited access to
systematically optimised substrates, necessary for highly robust
and sensitive screening assays. Moreover, several screens for
XPF-ERCC1 inhibitors have also been limited to screening
in silico or use truncated protein forms, leading to low hit
numbers and incomplete characterisation.20,21
The aim of this work was to generate and validate a highly
sensitive, scalable, robust assay for XPF-ERCC1 activity with a
broad dynamic range for use in high-throughput inhibitor
screens. The assay we describe utilises full-length XPF-ERCC1
and fork DNA structures which give high DNA duplex stability
whilst conferring sensitivity. The position of the fluorophore
and quencher relative to the junction has been varied to
optimise this assay, and importantly the use of full-length
XPF-ERCC1 gives potential for optimal inhibitor selectivity in
comparison to truncated protein, as well as the opportunity to
explore other modes of inhibition, such as allosteric approaches.
Full-length XPF-ERCC1 complex was purified from insect cells
using a baculovirus expression system [Fig. S1A (ESI†)].22 An XPF
active site substitution mutant D676A (XPFD676A-ERCC1), devoid of
nuclease activity, was also purified as a control for contaminating
insect cell nuclease activity.
We initially characterised the activity of XPF-ERCC1 using a
‘simple fork’ structure. This was labelled at the 30-terminus of the
single-stranded arm with a fluorescent CY3, a bright and stable
fluorophore (Fig. 1A). The assays employed a fixed concentration of
the divalent cations previously reported to support the activity
of XPF-ERCC1, (Mg2+ and Mn2+) and increasing concentrations of
XPF-ERCC1 within the range previously reported to be active on
this type of substrate (10 to 70 nM), with a 60 minute incubation
using a fixed, excess concentration of substrate (100 nM) (Fig. 1B).
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Activity could be observed for XPF-ERCC1 at concentrations as low
as 10 nM with greater activity in the Mn2+ buﬀer. As expected,
XPFD676A-ERCC1 (lanes marked: ND) supported no activity in either
buﬀer when present at the highest concentration (70 nM). There
have been reports of analysis of XPF-ERCC1 activities at both
30 1C and 37 1C. Here, we determined the fork substrate to be
equivalently digested by 40 nM XPF-ERCC1 at both temperatures
(Fig. S1B, ESI†), suggesting that activity is independent of
temperature within this range.
The data presented in Fig. 1B implied that a major determi-
nant of XPF-ERCC1 activity within our system is the divalent
cation present. We consequently explored XPF-ERCC1 activity
over a range of both Mg2+ and Mn2+ concentrations. XPF-ERCC1
activity is maximal at 1 mM Mn2+, while only weak activity is
observed at concentrations up to 10 mM Mg2+ (Fig. 1C and Fig.
S1C, ESI†), as previously rereported.16 We therefore employed
Mn2+, which supports greater XPF nuclease activity, at 1 mM for
further optimisation experiments. Finally, we carefully mapped the
major cleavage site of XPF-ERCC1 on this simple 30-fluor-labelled
fork substrate by generating a marker ladder containing 30-fluor-
labelled oligonucleotides of 2-nucleotide incremental sizes that
flank the predicted incision position. This revealed that the major-
ity (over 90%) of released products were 23-nucleotides in length,
corresponding to a cleavage site 2-nucleotides 50 to the fork
junction (Fig. 1D).
Having established optimal conditions for XPF-ERCC1 analysis,
we varied the position of the fluorophore within the single-stranded
arm of our fork substrates and analysed the eﬀect on activity.
This was in anticipation of including a quencher moiety on the
strand opposing the fluorescently labelled strand. This would
permit the establishment of a real-time fluorescence incision assay,
in which dsDNA cleaving by XPF-ERCC1 uncouples the fluorophore
and quencher leading to increased fluorescence. This readout can
subsequently be used to quantify enzyme activity and derive kinetic
measurements.
In order that the fluorescent moiety can be uncoupled from the
quencher incorporated elsewhere in the substrate, it is necessary to
place the fluorophore on one of the substrate arms, distal to the
major XPF-ERCC1 cut site, mindful that the location of the fluoro-
phore might itself further qualitatively and quantitatively modulate
the activity of XPF-ERCC1. Moreover, in order to optimally position
both a fluorophore and quencher on the substrates, as became
apparent (below), it might be necessary to move the fluorophore
from the extreme 30-terminus of the substrate arms. Consequently,
we generated a panel of substrates with a fluorophore positioned
8-nucleotides, 4-nucleotides and 2-nucleotides 30 to the fork
junction, and determined the activity of XPF-ERCC1 on these with
reference to the previously optimised substrate harbouring a
terminal 30-fluorophore. All the substrates were eﬃciently digested
by 10 nM XPF-ERCC1, although we detected a small shift in the
product size for the substrate bearing the fluorophore two nucleo-
tides from the fork junction (Fig. 2A). Further titration of XPF-
ERCC1 revealed that full cleavage of each fork substrate occurred at
concentrations between 10 and 20 nM in XPF-ERCC1 (Fig. S2, ESI†),
and therefore 20 nMwas selected as the lowest concentration for all
further analysis. By running the reaction products on a gel adjacent
to the molecular weight markers we confirmed that placing the
moiety two nucleotides from the junction likely moves the incision
position by a single nucleotide to a position 3-nucleotides from the
junction (Fig. 2B). This implies that the presence of the fluorophore
so close to the junction interferes sterically with the enzyme, altering
its position of incision.
Having established that XPF-ERCC1 is equally capable of digest-
ing substrates with the fluorophore at various positions along the
fork arm, with the caveat that the incision site might be altered by
positioning the fluorophore close to the junction, we next designed
a panel of substrates containing a Black Hole Quencher (BHQ).
This has excellent spectral overlap with the Quasar 570 dye on the
Fig. 1 (A) Control fork. The 30- and 50-direction are consistent through-
out. (B) Validation of XPF-ERCC1 (XE) activity on a known substrate at
varying XE concentrations and in the presence of 2 mM of Mn2+ or Mg2+.
Incubation was at 37 1C for 60 min in the presence of the control fork
(100 nM). The XPFD676A-ERCC1 inactive ‘nuclease dead’ (ND) form of XE
was used as a control to demonstrate that nuclease activity is intrinsic to
the XE protein. (C) Determination of optimum divalent cation species and
concentration. The control fork (100 nM) was incubated with XE (40 nM),
and varying concentrations of Mg2+ or Mn2+, for 60 min at 37 1C. For both
(B) and (C) the samples were analysed on a 10% denaturing PAGE gel.
(D) High-resolution 20% denaturing gel where substrate and reaction
product were run alongside multiple marker oligonucleotides with mole-
cular weights close to the predicted XE product size to determine the
major cleavage site on the control fork. Reactions were performed as in
panel (A) and (B), with 1 mM Mn2+. ND = XPFD676A-ERCC1.
Fig. 2 (A) Eﬀect of varying the fluorophore position on the simple fork
substrate. The fluorophore was positioned at 8, 4, and 2 nucleotides 30 to
the fork junction (Forks 1, 2 and 3, respectively) to evaluate whether it
aﬀected the activity of the XE. The diﬀerent forks (100 nM) were incubated
at 37 1C for 60 min, in the presence of 1 mM Mn2+ and varying concentra-
tions of XE, and analysed on preheated 12.5% denaturing PAGE gels.
(B) Direct comparison of major cleavage products of the four substrates
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opposing strand. The aim of this work was to generate a substrate
that is digested with maximal eﬃciency by XPF-ERCC1 simulta-
neously providing a stable fluorescent signal associated with a low
signal:noise and broad dynamic range. To achieve this we took an
empirical approach, placing the BHQ quencher at various positions
on the strand opposing the fluorophore, utilising substrates that
contained a fluorophore 8-, 4-, and 2-nucleotides 30 to the fork
junction. Preliminary experiments suggested that placing the fluoro-
phore at the 30-terminus of the fork led to poor quenching for all
BHQ positions due to the substantial spatial separation between the
fluorophore and quencher when the latter is terminally located.
Examination of substrates containing the fluorophore
8-nucleotides 30 to the fork junction combined with quencher
located 5-nucleotides 30 to the junction on the opposing strand
(Fork 1.1), 3-nucleotides 30 to the junction (Fork 1.2), at the
junction (Fork 1.3) or 2-nucleotides 50 to the junction (Fork 1.4)
in the single strand region revealed an XPF-ERCC1 sensitivity to
the quencher location (Fig. 3A).When the quencher is located within
the duplex region, XPF-ERCC1 makes a series of incisions and loses
selectivity, no longer producing a single major incision to release a
23-nucleotide product as observed with the control substrate lacking
the quencher moiety. Nevertheless, despite the eﬀect on cleavage
position selectivity, the overall eﬃciency of substrate cleavage is not
substantially impacted by the position of the quencher.
Equivalent experiments were performed on substrates
(Forks 2.1, 2.2, 2.3 and 2.4) containing the fluorophore four
nucleotides to the 30-side of the fork junction. This generated
very similar data (Fig. 3B), where placement of the quencher
within the duplex region produced a mixture of incision
products. Finally, we examined the XPF-ERCC1 cleavage char-
acteristics on substrates where the fluorophore was placed two
nucleotides to the 30-side of the fork junction in conjunction
with the same set of quencher locations used in Fig. 3A and B
(substrates Fork 3.1, 3.2, 3.3 and 3.4). These structures have the
advantage that the fluorophore and quencher are in closer
proximity than when the fluorophore is located closer to the
30-terminus. However, a more complex pattern of incisions was
observed for all substrates, regardless of the location of
quencher (Fig. 3C). We propose that the presence of both a
fluorophore and quencher in the vicinity of the fork junction
region, a critical feature for substrate recognition and verifica-
tion by XPF-ERCC1, interferes substantially with these pro-
cesses, changing the cleavage site. A summary gel provides
direct comparison of the qualitative and quantitative aspects of
digestion characteristics (Fig. S3, ESI†). Based on the above
analyses, we did not pursue any of the DNA structures where
the quencher was located in the duplex region of the substrate
(Forks 1.1, 1.2, 2.1, 2.2), as the multiple species could significantly
reduce the robustness of the fluorogenic assay. In addition, none
of the structures where the fluorophore is located 2-nucleotides
from the junction, regardless of quencher combination, were
further pursued since these also formed a complex array of
products (3.1, 3.2, 3.3, 3.4).
High-throughput screens require non-gel-based assays.
Development of a multi-well plate assay was necessary, where
the generation of the fluorescent signal acts as a readout of
XPF-ERCC1 activity. Initial assays using 100 nM DNA substrate
showed reasonable signal:noise, and minimal fluorescence
photobleaching. Optimisation led to the DNA concentration
being raised to 200 nM, which was shown to increase the
signal:noise, as well as the overall fluorescence readout. We
then monitored the fluorogenic output of substrates 1.3, 1.4,
2.3 and 2.4 in a 384-well format as a function of time, with
readings taken every minute for 30 min (Fig. 4A). Pleasingly all
substrates produced little background fluorescence over this
time course, indicating that all were stable under the reaction
conditions, and that non-specific background fluorescence
would not be a confounding feature in the assay. Substrates
were further screened against varying concentrations of
XPF-ERCC1, and this indicated that 40 nM was optimal for a
robust high throughput assay (Fig. S4, ESI†).
Diﬀering maximum fluorescence outputs were detected, where
the substrate bearing the fluorescent moiety four nucleotides
Fig. 3 Eﬀect of varying the Black Hole Quencher (BHQ) position on Forks
1, 2, and 3. Four positions, 5, 3, 0, and 2-nucleotides from the junction,
on the strand opposing of that containing the fluorophore were functio-
nalised with BHQ (Forks 1.1, 1.2, 1.3 and 1.4, respectively) and their eﬀects
on XE binding activity were evaluated. The assays were run and analysed
under the conditions described in Fig. 2. The eﬀect of varying BHQ
location on Fork 1 is shown in panel A, on Fork 2 in panel B, where forks
containing the quench 5, 3, 0 and 2-nucleotides from the junction are
labelled Forks 2.1, 2.2, 2.3 and 2.4, respectively, and Fork 3 in panel C,
where forks containing the quench 5, 3, 0 and 2-nucleotides from the
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from the junction and the quencher at the junction (substrates 2.3)
produced a lower signal than those where the quencher was
positioned two nucleotides into the substrate arms (substrates 1.4
and 2.4), regardless of whether the fluorophore was located four or
eight nucleotides from the junction. Fork 1.3 produced the best
signal:noise (Fig. 4B) and the greatest dynamic range (Fig. 4A). It was
therefore designated the preferred substrate for further validation.
A requirement for high-throughput screening is good tem-
poral stability of the reaction substrate and products, as a
substantial period of time often elapses between assay termina-
tion and plate reading during large-scale screens. We therefore
measured the change in fluorescence of our optimal substrate
(1.3) alone and following incubation with 10–40 nM XPF-ERCC1
for 60 min. After reaction termination by EDTA addition and
incubation at room temperature for a further 135 minutes, the
assay substrate and its digestion products were shown to be
stable over the full extended period (Fig. 4C).
Finally, we validated our assay using a broad-spectrum small
molecule nuclease inhibitor, N-hydroxy-1,8-naphthalimide
(Fig. 4D). Employing the optimal substrate 1.3 in a 384 well
assay format we determined XPF-ERCC1 activity as a function
of inhibitor concentration. This produced an IC50 value of 32.9
mM (Fig. 4D), with a small standard error of the mean (1.1 mM)
which is very close to the literature value of 30 mM.20,23
DNA repair nucleases are an untapped class of drug targets.
Here we present a robust assay that has high signal:noise,
broad dynamic range, high sensitivity and long-term stability.
It will be useful for probing mechanistic enzymology and
characterising the functional impact of mutations in XPF and
interacting proteins such as SLX424 and XPA25 that are associated
with the devastating inherited syndromes Xeroderma pigmentosum,
Fanconi anaemia, Cockayne syndrome and Cerebro-Oculo-Facio-
Skeletal syndrome.14
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standard error of mean (n = 3). (C) Readout stability of Fork 1.3. A completed
384 well assay (run for 30 min) was left for a further 135 min at room
temperature and readings taken every 30 min The error bars indicate the
standard error of mean (n = 3). (D) The broad, nuclease inhibitorN-hydroxy-
1,8-naphthalimide (inset) was used to validate the assay. Fluorescence was
determined on the 384 well platform over a range of inhibitor concentra-
tions. Data were plotted and curve fitted using GraphPad Prism 7. The error
bars indicate the standard error of mean (n = 3).
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
Se
pt
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 9
/1
6/
20
19
 8
:5
3:
24
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
